Related Experiment Video
Updated: Mar 28, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Nectin-4 expression in vulvar squamous cell carcinoma
Frederik A Stuebs1, Antje Knöll2, Arndt Hartmann3
1Department of Gynecology and Obstetrics, Bavarian Cancer Research Center (BZKF), Erlangen University Hospital, Comprehensive Cancer Center, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstrasse 21-23, Erlangen, 91054, Germany. frederik.stuebs@uk-erlangen.de.
Abstract:
Therapy options for women with vulvar squamous cell carcinoma (VSCC) are limited. New strategies such as immune checkpoint inhibitors (ICI) or antibody-drug conjugates (ADC) are lacking. One potential target for the ADC Enfortumab Vedotin (EV) is Nectin-4. EV has been successfully used to treat metastatic urothelial carcinoma (mUC). Currently, there is limited data on the expression of Nectin-4 for VSCC. Our aim was therefore to investigate the expression of Nectin-4 in women with VSCC. In total, 219 formalin-fixed paraffin-embedded tissue (FFPE) samples of primary VSCC were collected between 2000 and 2021. A next generation tissue microarray (ngTMA) was constructed. The assessment of Nectin-4 expression was performed through the implementation of immunohistochemistry (IHC). We also performed NECTIN-4 fluorescence in situ hybridization (FISH) to evaluate amplification of Nectin-4. The median Nectin-4 H-score for membranous expression was 22.5, with 32.4% of VSCCs exhibiting moderate to strong expression. We could not show that Nectin-4 H-score (membranous) significantly influenced overall survival in addition to other prognostic factors. The rates of regional lymph node metastases, lymphatic vascular space involvement, G3-Grading, perineural sheath invasion and p16-/p53+ were highest in Nectin-4-negative VSCC. 28.8% of recurrent VSCC had moderate or strong expression of Nectin-4. None of the investigated VSCC (primary or recurrent) showed amplification of Nectin-4 in contrast to mUC. Nectin-4 could be a potential target in the therapy of women with VSCC. Further (pre-)clinical data is needed to evaluate the use of EV in therapy of women with VSCC.
Insights
Nectin-4 is expressed in vulvar squamous cell carcinoma (VSCC), suggesting it as a potential therapeutic target for antibody-drug conjugates (ADCs). However, Nectin-4 amplification was not observed in VSCC, unlike in metastatic urothelial carcinoma.
Area of Science:
- Gynecologic Oncology
- Cancer Biology
- Translational Research
Background:
- Therapeutic options for vulvar squamous cell carcinoma (VSCC) are limited.
- Novel treatment strategies, including immune checkpoint inhibitors (ICI) and antibody-drug conjugates (ADCs), are needed for VSCC.
- Nectin-4 is a target for the ADC Enfortumab Vedotin (EV), approved for metastatic urothelial carcinoma (mUC), but its expression in VSCC is largely uncharacterized.
Purpose of the Study:
- To investigate Nectin-4 expression in primary and recurrent VSCC.
- To assess the correlation between Nectin-4 expression and clinical prognostic factors.
- To evaluate Nectin-4 amplification in VSCC.
Main Methods:
- Analysis of 219 formalin-fixed paraffin-embedded (FFPE) VSCC samples using next-generation tissue microarrays (ngTMA).
- Immunohistochemistry (IHC) to assess Nectin-4 protein expression (H-score).
- Fluorescence in situ hybridization (FISH) to evaluate Nectin-4 gene amplification.
Main Results:
- Median Nectin-4 membranous H-score was 22.5, with 32.4% of VSCCs showing moderate to strong expression.
- Nectin-4 expression did not significantly impact overall survival but was associated with higher rates of lymph node metastases, lymphovascular invasion, G3-grading, perineural invasion, and p16-/p53+ status in Nectin-4-negative tumors.
- 28.8% of recurrent VSCC cases exhibited moderate to strong Nectin-4 expression. No Nectin-4 amplification was detected in any VSCC samples.
Conclusions:
- Nectin-4 is expressed in a subset of VSCC, indicating its potential as a therapeutic target for ADCs like EV.
- Nectin-4 expression status may correlate with adverse prognostic factors in VSCC.
- Further preclinical and clinical studies are warranted to explore EV efficacy in VSCC treatment.
Related Concept Videos
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
The Nucleolus
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Cancer Cell Migration through Invadopodia
Abnormal Proliferation

